Improved NMDP transplant outcomes

1
Improved NMDP transplant outcomes

• The curves in this presentation show outcomes of
  unrelated donor transplants facilitated by the
  NMDP during four time periods 1987-1995,
  1996-1998, 1999-2002, and 2003-2006
• In each disease category, survival has
  consistently, and sometimes dramatically,
  improved over time
• These curves were first published in the
  September 2008 supplement to Biology of Blood and
  Marrow TransplantationWeisdorf D, (Ed.). The
  National Marrow Donor Program reports to the
  community on 20 years of unrelated donor
  hematopoietic cell transplantation. Biol Blood
  Marrow Transplant. 200814(9, Suppl. 3)1-60.
• Learn more at the NMDP Web site
  www.marrow.org/md-20years

2
Guidelines for using NMDP slides

• The information and data in this presentation
  were prepared by the National Marrow Donor
  Program (NMDP). Each slide and/or information
  may be used in its entirety in presentations and
  publications as long as it is attributed to the
  National Marrow Donor Program.
• When used in presentations, NMDP slides should
  retain their content, appearance and design. (For
  instructions on copying the design along with the
  contents, see the notes to this slide.)
• Presentation notes are included to supplement the
  slide content. To print the notes, select Notes
  Pages in your printer window.
• To download the file to your computer, select
  Save As in the File menu.

3
Improved Transplant OutcomesSurvival of Adults
(age ³ 18 years) with Acute Myelogenous Leukemia
Pointwise p-value at 2 years lt 0.0001
4
Improved Transplant OutcomesSurvival of Adults
(age ³ 18 years) with Acute Myelogenous Leukemia
After HLA-Well-Matched HCT
Pointwise p-value at 2 years lt 0.0001
5
Improved Transplant OutcomesSurvival of Adults
(age ³ 18 years) with Acute Lymphoblastic Leukemia
Pointwise p-value at 2 years lt 0.0001
6
Improved Transplant OutcomesSurvival of Adults
(age ³ 18 years) with Myelodysplastic Syndromes
Pointwise p-value at 2 years lt 0.0001
7
Improved Transplant OutcomesSurvival of Adults
(age ³ 18 years) with Chronic Myelogenous Leukemia
Pointwise p-value at 2 years lt 0.0001
8
Improved Transplant OutcomesSurvival of Adults
(age ³ 18 years) with Severe Aplastic Anemia
Pointwise p-value at 2 years lt 0.0001
9
Improved Transplant OutcomesSurvival of Children
(age lt 18 years) with Acute Leukemia
Pointwise p-value at 2 years lt 0.0001
10
Improved Transplant OutcomesSurvival of Children
(age lt 18 years) with Acute Leukemia in First
Complete Remission (CR1) at Time of Transplant
Pointwise p-value at 2 years 0.0003
11
Improved Transplant OutcomesSurvival of Children
(age lt 18 years) with Acute Leukemia in Second
Complete Remission at Time of Transplant
Pointwise p-value at 2 years 0.0005
12
Improved Transplant OutcomesTransplant-Related
Mortality in Children (age lt 18 years) with Acute
Leukemia in First or Second Complete Remission at
Time of Transplant
Pointwise p-value at 1 year lt 0.0001
13
Improved Transplant OutcomesSurvival of Children
(age lt 18 years) with Acute Leukemia After
HLA-Well-Matched Unrelated Donor Transplant
Pointwise p-value at 2 years 0.0005
14
Improved Transplant OutcomesSurvival of Children
(age lt 18 years) with Acute Leukemia Transplanted
with HLA-mismatched Unrelated Donor Bone Marrow
Pointwise p-value at 2 years 0.008
15
Improved Transplant OutcomesSurvival of Children
(age lt 18 years) with Severe Aplastic Anemia
Pointwise p-value at 2 years lt 0.0001